Given that PDE4 is the major cAMP-hydrolyzing enzyme in inflammatory cells and that it is necessary for developing of inflammatory response [8,14,15,25], several studies showed beneficial effect of PDE4 inhibitors on such inflammatory diseases as asthma and chronic obstructive pulmonary disease (COPD) [16]. Here, PDE4A is linked to chronic obstructive pulmonary disease.